Pharvaris N.V. (NASDAQ:PHVS) Short Interest Up 48.7% in August

Posted by Francis Steltz on Sep 2nd, 2026

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) was the recipient of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 1,775,021 shares, an increase of 48.7% from the July 30th total of 1,193,401 shares. Based on an average daily volume of 638,201 shares, the days-to-cover ratio is presently 2.8 days. Approximately 2.7% of the shares of the stock are short sold.

Insider Transactions at Pharvaris

In other Pharvaris news, insider Anna Nijdam sold 2,670 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $30.87, for a total value of $82,422.90. Following the transaction, the insider owned 46,275 shares in the company, valued at approximately $1,428,509.25. This trade represents a 5.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the sale, the director directly owned 315,167 shares in the company, valued at approximately $11,185,276.83. This trade represents a 8.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 121,325 shares of company stock valued at $4,270,425 in the last 90 days.

Institutional Investors Weigh In On Pharvaris

Institutional investors have recently modified their holdings of the company. venBio Partners LLC acquired a new position in Pharvaris during the 2nd quarter worth about $160,569,809. Wellington Management Group LLP purchased a new stake in Pharvaris during the third quarter worth about $43,282,000. 5AM Venture Management LLC acquired a new stake in shares of Pharvaris during the second quarter worth about $27,581,008. California State Teachers Retirement System grew its holdings in shares of Pharvaris by 3,210.1% in the second quarter. California State Teachers Retirement System now owns 799,490 shares of the company’s stock valued at $27,646,000 after purchasing an additional 775,337 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP increased its stake in Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after buying an additional 772,583 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on PHVS shares. HC Wainwright reissued a “buy” rating on shares of Pharvaris in a research note on Friday, August 14th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a report on Thursday, August 13th. HSBC upgraded Pharvaris to an “overweight” rating in a research report on Thursday, August 13th. Citizens Jmp boosted their price objective on Pharvaris from $74.00 to $75.00 and gave the stock a “market outperform” rating in a research note on Thursday, August 13th. Finally, Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $51.08.

View Our Latest Report on PHVS

Pharvaris Stock Performance

Shares of Pharvaris stock traded down $0.58 on Wednesday, reaching $34.35. The company had a trading volume of 92,911 shares, compared to its average volume of 337,542. The firm’s 50 day moving average price is $34.67 and its two-hundred day moving average price is $30.88. Pharvaris has a 52-week low of $20.65 and a 52-week high of $38.13. The firm has a market cap of $2.25 billion, a PE ratio of -11.26 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, sell-side analysts predict that Pharvaris will post -3.15 EPS for the current year.

Pharvaris Company Profile

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.